PharmaVentures conducted a thorough company screening and evaluation assessment to identify and prioritise potential acquirers with a good match for the technology and a strong strategic need in the relevant therapy area. Following the screening, within the space of a month PharmaVentures’ transaction team approached all the target companies with the value proposition using a non-confidential information package.

PharmaVentures managed the exchange of Confidential Disclosure Agreements followed by providing confidential information in a memorandum, supporting management presentations and managed access to the dataroom. Finally PharmaVentures provided negotiations support leading to the sale of Dow’s API manufacturing assets to Dr Reddy’s Laboratories.